1Vieweg J,Rosenthal FM,Bannerji R,et al.Immunotherapy of prostate cancer in the dunning rat model:use of cytokine gene modified tumor vaccines.Cancer Res,1994,54 (7):1760-1765
2Berger U,Wilson P,McClelland RA,et al.Immunocytochemical detection of 1,25-dihydroxyvitamin D receptors in normal human tissues.J Clin Endocrinol Metab,1988,67:607 -613.
4Garland CF,Gorland FC,Gorham ED,et al.The Role of Vitamin D in Cancer Prevention.Am J Public Health,2005.
5Giovannucci E.The epidemiology of Vitamin D and colorectal cancer:rencentfings.Curr Opin Gastroenterol,2006,22 (1):24 -29.
6Woo TC,Choo R,Jamieson M,et al.Pilot study:potential role of vitamin D (Cholecalciferol) in patients with PSA relapse after definitive therapy.Nutr Cancer,2005,51 (1):32 -36.
7Yang ES,Burnstein KL.Vitamin D inhibits G1 to S progression in LNCaP prostate cancer cells through p27Kip1 stabilizationand Cdk2 mislocalization to the cytoplasm.J Biol Chem,2003,278 (47):46862-46868.
8Polek TC,Stewart LV,Ryu EJ,et al.p53 Is required for 1,25-dihydroxyvitamin D3-induced G0 arrest but is not required for G1 accumulation or apoptosis of LNCaP prostate cancer cells.Endocrinology,2003,144(1):50 -60.
9Guzey M,Kitada S,Reed JC.Apoptosis induction by 1 alpha,25-dihydroxyvitamin D3 in prostate cancer.Mol Cancer Ther,2002,1 (9):667-677.
10Stewart LV,Weigel NL.Role of insulin-like growth factor binding proteins in 1 alpha,25 -dihydroxyvitamin D (3) -induced growth inhibition of human prostate cancer cells.Prostate,2005,64(1):9 -19.